JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

NVS

149.86

+0.11%↑

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

NVS

149.86

+0.11%↑

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

NVS

149.86

+0.11%↑

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

NVS

149.86

+0.11%↑

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

NVS

149.86

+0.11%↑

Home・Listă Acțiuni・Eli Lilly and Co.

Eli Lilly and Co.

Închisă

SectorSănătate

1,007.5 -0.79

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

995

Maxim

1015.5

Indicatori cheie
By Trading Economics
Venit	758M 7.4B
Vânzări	507M 20B
P/E Medie Sector	34.327 51.415
EPS	8.55
Randament dividend	0.66
Marjă de profit	37.355
Angajați	50,000
EBITDA	971M 9.4B

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+24.33% upside

Dividende
By Dow Jones
Randament dividend Medie Sector	0.66% 2.34%
Următoarele câștiguri	5 aug. 2026
Data viitoare de dividende	10 iun. 2026
Următoarea dată ex-dividende	15 mai 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	87B 862B
Deschiderea anterioară	1008.29
Închiderea anterioară	1007.5

Sentimentul știrilor

By Acuity

33%

67%

93 / 346 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

N/A / 884.54 Suport & Rezistență

Eli Lilly and Co. Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

30 apr. 2026, 12:01 UTC

Câștiguri

Principalele dinamici ale pieței

Eli Lilly Shares Jump On Guidance Boost, Earnings Above Expectations

7 mai 2026, 09:30 UTC

Câștiguri

America's Weight-Loss Drug Boom Is Going Global -- Heard on the Street -- WSJ

6 mai 2026, 12:36 UTC

Câștiguri

Novo's Weight-Loss Pill Heaps Pressure on Eli Lilly. Stock Jumps After Earnings. -- Barrons.com

6 mai 2026, 10:12 UTC

Câștiguri

Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly. -- Barrons.com

6 mai 2026, 09:58 UTC

Câștiguri

Novo Nordisk Shares Jump on Strong Demand for Wegovy Pill -- 2nd Update

30 apr. 2026, 20:59 UTC

Acțiuni populare

Stocks to Watch Recap: Blue Owl, Alphabet, Qualcomm, Meta Platforms -- WSJ

30 apr. 2026, 20:12 UTC

Câștiguri

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30 apr. 2026, 16:43 UTC

Câștiguri

Eli Lilly Shares Jump 10% as Mounjaro, Zepbound Fuel Massive Growth -- WSJ

30 apr. 2026, 16:10 UTC

Market Talk

Eli Lilly Expecting A Push to Extend Medicare GLP-1 Coverage -- Market Talk

30 apr. 2026, 15:13 UTC

Câștiguri

Update: Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30 apr. 2026, 14:58 UTC

Câștiguri

Lilly CEO: Direct-to-Consumer Channel Popularity Will Continue, Become Useful in Other Kinds of Drugs

30 apr. 2026, 14:53 UTC

Câștiguri

Lilly Expects Government to Push to Get GLP-1 Medicare Coverage for 2028, CEO Says

30 apr. 2026, 14:50 UTC

Câștiguri

Lilly Expects Strong Persistence in Medicare Population for GLP-1s, President of Lilly USA Says

30 apr. 2026, 14:42 UTC

Câștiguri

Gaining Incremental Market Share in GLP-1s Getting Harder, President of Lilly International Says

30 apr. 2026, 14:39 UTC

Câștiguri

Lilly CEO: GLP-1 Unit Economics Dependent on Fixed Costs Unmoved by Volume

30 apr. 2026, 14:35 UTC

Câștiguri

Lilly CEO: GLP-1 Price Cuts Result in Large Volume Expansions

30 apr. 2026, 14:24 UTC

Câștiguri

Lilly to Begin Full-Scale Consumer Promotion, Including TV Ads, of Foundayo in 3Q, CFO Says

30 apr. 2026, 14:17 UTC

Câștiguri

Lilly CFO: Loss of Medicaid Access in Some States Hurt 1Q Prescription Growth By High Single Digits

30 apr. 2026, 13:56 UTC

Câștiguri

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30 apr. 2026, 13:37 UTC

Acțiuni populare

Stocks to Watch: Alphabet, Qualcomm, Meta Platforms, Eli Lilly -- WSJ

30 apr. 2026, 12:32 UTC

Market Talk

Câștiguri

Eli Lilly CEO Says Early Foundayo Results Are Strong -- Market Talk

30 apr. 2026, 12:29 UTC

Market Talk

Câștiguri

Eli Lilly CEO Says Foundayo Adoption Could Take Time -- Market Talk

30 apr. 2026, 12:23 UTC

Market Talk

Câștiguri

Eli Lilly CEO Says International Demand for GLP-1s Is Ramping Up -- Market Talk

30 apr. 2026, 12:10 UTC

Câștiguri

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30 apr. 2026, 12:08 UTC

Câștiguri

Eli Lilly Sales, Profits Surge on Weight-Loss Drugs -- WSJ

30 apr. 2026, 12:04 UTC

Market Talk

Câștiguri

Eli Lilly's GLP-1 Party Has No End in Sight -- Market Talk

30 apr. 2026, 11:39 UTC

Acțiuni populare

Stocks to Watch: Alphabet, Qualcomm, Meta Platforms, Eli Lilly -- WSJ

30 apr. 2026, 11:08 UTC

Câștiguri

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30 apr. 2026, 10:50 UTC

Câștiguri

Eli Lilly Raises 2026 Performance Margin View to 47%-48.5% From 46%-47.5% >LLY

30 apr. 2026, 10:49 UTC

Câștiguri

Eli Lilly Had Seen 2026 Revenue $80B-$83B, Adjusted EPS $33.50-$35.00 >LLY

Comparație

Modificare preț

Eli Lilly and Co. Așteptări

Obiectiv de preț

By TipRanks

24.33% sus

Prognoză pe 12 luni

Medie 1,262.85 USD 24.33%

Maxim 1,500 USD

Minim 850 USD

În baza a 22 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruEli Lilly and Co. - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

22 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 22 analiști care au acordat evaluări ale acțiunilor Eli Lilly and Co. - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

N/A / 884.54Suport & Rezistență

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

93 / 346 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.